Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from OMER

Omeros Q1 Earnings Call Highlights

Omeros (NASDAQ:OMER) reported first-quarter 2026 net income of $56.1 million, or $0.78 per share, as the company began commercial sales of YARTEMLEA, its recently approved treatment for hematopoietic stem cell transplant-associated thrombotic microangiopathy, or TA-TMA. Chairman and Chief Executive

Breakout Momentum Plays You Need to Know About

Breakout Momentum Plays You Need to Know About

Three stocks may draw the attention of momentum investors—QURE spiked in September, OMER in October, and SDST has almost 1,000% in upside potential.

Hims & Hers, Salesforce, Omeros, United Airlines, And Sea Ltd: Why These 5 Stocks Are On Investors' Radars Today

Hims & Hers, Salesforce, Omeros, United Airlines, And Sea Ltd: Why These 5 Stocks Are On Investors' Radars Today

Major U.S. indices ended mixed on Wednesday, with the Dow Jones Industrial Average slipping 0.04% to 46,253.31. The SP 500 added 0.4% to 6,671.06, while the Nasdaq climbed nearly 0.7% to 22,670.08.These are the top stocks that gained the attention of retail traders and investors through the day: Hims Hers…

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Omeros Stock Skyrockets After Novo Nordisk Strikes $2.1B Rare Disease Drug Deal

Biotech breakthroughs are reshaping the pharmaceutical landscape, sparking lucrative deals and redefining the future of rare disease treatment. Omeros Corporation (NASDAQ:OMER) stock is rallying on Wednesday, with a session volume of 89.21 million versus the average volume of 1.11 million, as per data from Benzinga Pro.

Omeros: Q1 Earnings Insights

Omeros (NASDAQ:OMER) reported its Q1 earnings results on Tuesday, May 10, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings Omeros beat estimated earnings by 25.35%, reporting an EPS of $-0.53 versus an estimate of $-0.71.

Omeros Earnings Preview

Omeros (NASDAQ:OMER) is set to give its latest quarterly earnings report on Tuesday, 2022-05-10. Here's what investors need to know before the announcement. Analysts estimate that Omeros will report an earnings per share (EPS) of $-0.71.

Omeros's Return On Capital Employed Insights

According to Benzinga Pro, during Q4, Omeros (NASDAQ:OMER) earned $280.62 million, a 1336.05% increase from the preceding quarter. Omeros also posted a total of $30.84 million in sales, a 2.8% increase since Q3.

inkl

Read news from The Economist, FT, and more,
with one subscription

Omeros Submits Response To FDA Regarding Narsoplimab Application In HSCT-TMA

Omeros Submits Response To FDA Regarding Narsoplimab Application In HSCT-TMA

Omeros Corporation (NASDAQ: OMER) has submitted to the FDA its response to Complete Response Letter for narsoplimab in hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA).

1

People

Shivdeep Dhaliwal

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

United Airlines

United Airlines Holdings

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Dow Jones Industrial Average

Places

390,693 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play